Collaborative Consult: Cases, Patient Reflection, and Discussions – What’s New in Pediatric Atopic Dermatitis (ID: I830a) Question Title * 1. How many years have you been in practice? >21 11-20 1-10 <1 Question Title * 2. How many patients with pediatric atopic dermatitis do you manage per week? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 3. Please select the option that best describes your practice setting. Academic medical center Community medical center VA, DOD, or other government Managed care Research Pharmaceutical industry Question Title * 4. After participating in this activity, how confident are you in the management of patients with atopic dermatitis in your practice? Very confident Confident Little confidence No confidence Question Title * 5. After participating in this activity, do you intend to incorporate newly FDA-approved therapies into your clinical practice for patients with moderate-to-severe atopic dermatitis aged ≥6 months? Yes, immediately Will wait to hear from colleagues regarding experience with these agents in clinical practice Will wait until additional clinical trial data becomes available Will not incorporate into practice Question Title * 6. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Not committed I do not plan to make changes Not committed or do not plan to make changes (please indicate reason) Question Title * 7. Which of the following best describes the impact of this activity on your performance? I gained new strategies/skills/information I can apply to my area of practice I need more information before I can change my practice My practice is already consistent with the information presented This activity will not change my practice Question Title * 8. Which new strategies/skills/information have you gained as a result of participation? Please select all that apply. Increased understanding of the pathophysiologic differences of AD between pediatric & adult patients Increased knowledge of the immune dysregulation and pathogenesis in pediatric AD Greater awareness of the efficacy and safety of recently approved agents for the treatment of AD Improved understanding of emerging therapies' potential for the treatment of AD Increased awareness of the limitations of current guidelines and the need for updated guidelines Improved ability to incorporate effective multidisciplinary management strategies Better able to recognize when to switch treatment regimens Improved understanding of validated measures to assess disease severity and monitor AD progression Improved ability to incorporate shared decision making and patient education in clinical practice to improve patient outcomes Better understanding of when to refer patient to a specialist Question Title * 9. What barriers do you see to making changes in your practice? Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement or legal issues Conflicting guidelines or evidence Patient compliance and/or patient resource barriers Other (please specify) Question Title * 10. Please rate your level of agreement by checking the appropriate rating.After participating in today’s activity, I am now better able to: Strongly Disagree Disagree Neutral Agree Strongly Agree Describe the immunopathogenesis of AD Describe the immunopathogenesis of AD Strongly Disagree Describe the immunopathogenesis of AD Disagree Describe the immunopathogenesis of AD Neutral Describe the immunopathogenesis of AD Agree Describe the immunopathogenesis of AD Strongly Agree Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Strongly Disagree Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Disagree Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Neutral Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Agree Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Strongly Agree Apply evidence-based guideline recommendations to the treatment of pediatric AD Apply evidence-based guideline recommendations to the treatment of pediatric AD Strongly Disagree Apply evidence-based guideline recommendations to the treatment of pediatric AD Disagree Apply evidence-based guideline recommendations to the treatment of pediatric AD Neutral Apply evidence-based guideline recommendations to the treatment of pediatric AD Agree Apply evidence-based guideline recommendations to the treatment of pediatric AD Strongly Agree Question Title * 11. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree The following faculty presenter Anthony J. Mancini, MD, FAAP, FAAD effectively: Strongly Disagree Disagree Neutral Agree Strongly Agree Presented the Material Presented the Material Strongly Disagree Presented the Material Disagree Presented the Material Neutral Presented the Material Agree Presented the Material Strongly Agree Avoided Commercial Bias Avoided Commercial Bias Strongly Disagree Avoided Commercial Bias Disagree Avoided Commercial Bias Neutral Avoided Commercial Bias Agree Avoided Commercial Bias Strongly Agree Question Title * 12. Please rate your level of agreement by checking the appropriate rating.The content presented: Strongly Disagree Disagree Neutral Agree Strongly Agree Enhanced my current knowledge base Enhanced my current knowledge base Strongly Disagree Enhanced my current knowledge base Disagree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Agree Enhanced my current knowledge base Strongly Agree Addressed my most pressing questions Addressed my most pressing questions Strongly Disagree Addressed my most pressing questions Disagree Addressed my most pressing questions Neutral Addressed my most pressing questions Agree Addressed my most pressing questions Strongly Agree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly Disagree Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Strongly Agree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly Disagree Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Strongly Agree Avoided commercial bias or influence Avoided commercial bias or influence Strongly Disagree Avoided commercial bias or influence Disagree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Agree Avoided commercial bias or influence Strongly Agree Question Title * 13. If you indicated that you perceived commercial bias or influence, please describe: Question Title * 14. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 15. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for atopic dermatitis or related disease state: Done